Sarepta Therapeutics, Inc.SRPTEarnings & Financial Report

Nasdaq · pharmaceutical industry

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

Revenue

$370.0M

Gross Profit

N/A

Operating Profit

$-103.4M

Net Profit

$-179.9M

Gross Margin

N/A

Operating Margin

-27.9%

Net Margin

-48.6%

YoY Growth

-13.9%

EPS

$-1.80

Financial Flow

Sarepta Therapeutics, Inc. Q3 2025 Financial Summary

Sarepta Therapeutics, Inc. reported revenue of $370.0M for Q3 2025, with a net profit of $-179.9M (-48.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$370.0M
Net Profit	$-179.9M
Gross Margin	N/A
Operating Margin	-27.9%
Report Period	Q3 2025

Sarepta Therapeutics, Inc. Annual Revenue by Year

Sarepta Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.8B).

Year	Annual Revenue
2024	$1.8B
2023	$1.1B
2022	$843.8M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$365.1M	$359.5M	$360.5M	$429.8M	$638.2M	$611.5M	$513.1M	$370.0M
YoY Growth	54.7%	55.3%	50.9%	38.9%	74.8%	70.1%	42.3%	-13.9%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$3.26B	$3.22B	$3.42B	$3.60B	$3.96B	$3.47B	$3.68B	$3.49B
Liabilities	$2.41B	$2.26B	$2.35B	$2.38B	$2.44B	$2.32B	$2.32B	$2.17B
Equity	$859.3M	$961.2M	$1.08B	$1.22B	$1.53B	$1.14B	$1.36B	$1.32B